UHPLC-MS/MS Assay for Quantification of Legubicin, a Novel Doxorubicin-Based Legumain-Activated Prodrug, and Its Application to Pharmacokinetic and Tissue Distribution Studies
Molecules · 08.02.2024 · 29 (4) · 775
DOI: 10.3390/molecules29040775 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 08.02.2024. Verfasst von Liyuan Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201203, China. Hauptthemen laut MEDLINE: Prodrugs, Neoplasms, Cysteine Endopeptidases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Legubicin, a novel prodrug based on doxorubicin, has both albumin-binding and legumain-activating properties. The aim of this study was to develop and validate a UHPLC-MS/MS method for investigating the in vivo pharmacokinetics and tissue distribution profiles of legubicin in rats and tumor-bearing mice following intravenous administration, and to compare this prodrug with the positive control drug doxorubicin. The study employed a UHLC-MS/MS method to determine the levels of albumin-bound of legubicin and two metabolites (free Leu-DOX and DOX) in plasma, tumor, and tissue samples. This method was validated for good selectivity, high sensitivity, excellent extraction recovery, and short run time. The results showed that legubicin was present in the circulation in vivo mainly in a protein-bound form with larger AUC values and lower clearance and distribution, and essentially released small amounts of doxorubicin. Compared to administration of equimolar doses of doxorubicin, legubicin showed increased exposure of the active drug in the tumor and decreased the level of the active drug in the heart and kidney. This study provides valuable information on the pharmacokinetics and tissue distribution of legubicin, implicating its potential as a novel and effective drug candidate for anti-cancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201203, China.
- Shanghai Innostar Bio-Tech Co., Ltd., China State Institute of Pharmaceutical Industry, Shanghai 201203, China.
- Shanghai Affinity Bio-Pharmaceuticals Co., Ltd., Shanghai 201203, China.
ORCID-Profile: Yan Chang
Zitieren
APA
Ma, L., Yu, Q., Zhuang, M., Yang, C., Liu, Y., Li, Y., Liu, C., Shen, X., & Chang, Y. (2024). UHPLC-MS/MS Assay for Quantification of Legubicin, a Novel Doxorubicin-Based Legumain-Activated Prodrug, and Its Application to Pharmacokinetic and Tissue Distribution Studies. Molecules, 29(4), 775. https://doi.org/10.3390/molecules29040775
Vancouver
Ma L, Yu Q, Zhuang M, Yang C, Liu Y, Li Y, et al. UHPLC-MS/MS Assay for Quantification of Legubicin, a Novel Doxorubicin-Based Legumain-Activated Prodrug, and Its Application to Pharmacokinetic and Tissue Distribution Studies. Molecules. 2024;29(4):775. doi:10.3390/molecules29040775
BibTeX
@article{Ma2024,
author = {Ma, Liyuan and Yu, Qiaoling and Zhuang, Meng and Yang, Chen and Liu, Yuan and Li, Yuling and Liu, Cheng and Shen, Xiaoyan and Chang, Yan},
title = {UHPLC-MS/MS Assay for Quantification of Legubicin, a Novel Doxorubicin-Based Legumain-Activated Prodrug, and Its Application to Pharmacokinetic and Tissue Distribution Studies},
journal = {Molecules},
year = {2024},
volume = {29},
number = {4},
pages = {775},
doi = {10.3390/molecules29040775}
}
EUVIMED